8067-24-1

Basic information

• Product Name: Dihydroergotoxine mesylate
• Synonyms: cck179;circanol;co-dergocrinemesylate;dihydroergotoxinemesilate;dihydroergotoxinemethanesulfonate;dihydroergotoxinemethanesulphonate;dihydroergotoxinemonomethanesulfonate(salt);dihydroergotoxinmesylate
• CAS NO: 8067-24-1
• Molecular Formula: C20H29N3O5S
• Molecular Weight: 423.53
• EINECS: 249-539-5
• Mol File: 8067-24-1.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 899.5 ºC at 760 mmHg
• Flash Point: 497.8 ºC
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 1.77E-30mmHg at 25°C
• Refractive Index: 1.66
• Storage Temp.: Store at RT
• CAS DataBase Reference: Dihydroergotoxine mesylate(CAS DataBase Reference)
• NIST Chemistry Reference: Dihydroergotoxine mesylate(8067-24-1)
• EPA Substance Registry System: Dihydroergotoxine mesylate(8067-24-1)

Safety Data

• Hazard Codes: T
• Statements: 60
• Safety Statements: 53-36/37/39-45
• RIDADR: 1544
• RTECS: KE8800000
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 8067-24-1(Hazardous Substances Data)

Usage

Description

Dihydroergotoxine mesylate is a mixture of hydrogenated ergot alkaloids, including the methanesulfonic acid salts of dihydroergocornine, dihydroergocristine, and dihydroergotoxine. It is known for its ability to block reflex vasodilation and vasoconstriction induced by norepinephrine, as well as inhibiting norepinephrine-induced cAMP production in rat brain cortical homogenates. Additionally, it exhibits erectogenic properties in rats.
Used in Pharmaceutical Industry:
Dihydroergotoxine mesylate is used as a therapeutic agent for the symptomatic treatment of mild to moderate dementia in the elderly. It is believed to help improve cognitive function and memory in these patients, although its value is not yet fully established.
Used in Migraine Treatment:
Dihydroergotoxine mesylate is used as a treatment for migraine headaches, where it may help to alleviate the symptoms and reduce the frequency of migraine attacks.
Used in Vascular Dementia Treatment:
Dihydroergotoxine mesylate is also used in the treatment of vascular dementias, where it may help improve blood flow to the brain and support cognitive function.

Pharmacology

The metabolic effects of ergoloid mesylates (Hydergine) may include enhancement of noradrenergic, dopaminergic and serotoninergic neurotransmission (Weil,1988) and reduction of free radicals. Schneider and Olin (1994) reviewed 151 reports on the use of Hydergine in senile dementia, but only 47 of these trials (31%) met strict criteria for meta-analysis. ACochrane review (Olin et al., 2001) confirmed that patients with VaD appeared to benefit more than patients with AD in terms of cognition,clinical global ratings and combined measures. However, compared with placebo, efficacy was very modest. Thus, there are no grounds to recommend its use.

InChI:InChI=1/C33H45N5O5/c1-7-31(4,5)27-29(40)37-13-9-12-25(37)33(42)38(27)30(41)32(43-33,18(2)3)35-28(39)20-14-22-21-10-8-11-23-26(21)19(16-34-23)15-24(22)36(6)17-20/h8,10-11,16,18,20,22,24-25,27,34,42H,7,9,12-15,17H2,1-6H3,(H,35,39)